EntryPoint Capital’s Ascendis Pharma A/S ASND Stock Holding History

EntryPoint Capital’s Portfolio ASND Stock Details ASND Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-193	Closed	-$29.2K	–	889
2024 Q1	$29.2K	Sell	193 -60	-24%	-$8.56K	0.03%	968
2023 Q4	$31.9K	Buy	+253	New	+$25.2K	0.03%	902

Other funds holding ASND

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

Westfield Capital Management Boston, Massachusetts $23.8B AUM 49.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Artisan Partners Milwaukee, Wisconsin $62.3B AUM 26.25% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

EntryPoint Capital's ASND Position: Q2 2024 in Review

EntryPoint Capital sold out of Ascendis Pharma A/S (ASND) in Q2 2024, closing a stake of 193 shares — an estimated $29.2K sold.

EntryPoint Capital first reported a position in ASND in Q4 2023 and held it in 2 quarters. The position peaked at $31.9K in Q4 2023. 203 funds tracked by Wall St. Rank hold ASND as of Q2 2024.

EntryPoint Capital reported no remaining Ascendis Pharma A/S position as of Q2 2024 after selling out during the quarter.
EntryPoint Capital sold 193 Ascendis Pharma A/S shares in Q2 2024, an estimated $29.2K.
EntryPoint Capital first reported a position in Ascendis Pharma A/S in Q4 2023 and held it in 2 quarters.
EntryPoint Capital's Ascendis Pharma A/S position peaked at $31.9K in Q4 2023.
203 funds tracked by Wall St. Rank held Ascendis Pharma A/S as of Q2 2024.

Based on EntryPoint Capital's 13F filing for Q2 2024, filed 13 Aug 2024.